Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. ( (AU:RAC) ) has issued an update.
Racura Oncology has disclosed that a November 2025 cashless exercise of 4 million unlisted options by its current and former chief executives resulted in an administrative error, with 179,242 more shares being issued and recorded than intended. The company has placed a holding lock on these excess shares and plans a selective buyback and cancellation, subject to approval at its upcoming annual meeting, in a move aimed at rectifying the capital structure discrepancy and reassuring shareholders about governance and disclosure practices.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company focused on cancer therapeutics. Its lead asset, RCDS1 (E,E-bisantrene), is a small-molecule anticancer agent targeting G4-DNA and RNA to inhibit the cancer growth regulator MYC, and is being advanced as the proprietary formulation RC220 across multiple oncology indications, including acute myeloid leukaemia, EGFR-mutant non-small cell lung cancer, and solid tumours in combination with doxorubicin. The company holds recent composition-of-matter intellectual property providing 20 years of patent protection over RCDS1 and collaborates with leading international research institutions while exploring partnerships, licensing deals and potential M&A to accelerate global access to RC220.
Average Trading Volume: 216,234
Technical Sentiment Signal: Buy
Current Market Cap: A$415.6M
For a thorough assessment of RAC stock, go to TipRanks’ Stock Analysis page.